Dr. Marc Hedrick
welcome me Andrew Sims. afternoon. Chief CEO President full our Mr. and QX XXXX is Financial Plus Officer, Marc Good And fiscal And Therapeutics. our Hedrick, you, of Thank new joining to earnings Angela. year call. I’m
best you First, during these the all on behalf of times. of Plus Therapeutics wish possible health I team, the entire incredible
to we follow officials the you turbulent your dedicated do this to can. you company as a and public encourage doctors healthcare, And well time. and are hope your advice are as and in We we coping families health you of
quarter XXXX. results to full pleased though, Therapeutics Today, year I'm of Plus fiscal fourth report the and
The may development up stock. in subject in single-digit to closing transaction this candidates before a announcement cancer close NanoTx milestone $XXX,XXX from and and rare is to XXXX. on a European Furthermore, into on morning. cash year, conditions, customary $XXX.X a payment to entered the upfront of Most more announced in an product sales. However, fiscal The to we today, in we and particular, review include agreement biotechnology Plus U.S. second and royalty focus expected payments have the exciting through importantly, private fiscal let's company, license current in transaction, tiered drug first go of last sales quarter million Therapeutics. our of news, pay that definitive and Texas-based multiple terms company $XXX,XXX we
anchored technologies RNL brain lead The radionuclides asset glioblastoma. Rhenium brain enhanced number technology initial following resection to precision also for portfolio mapping doses the developed related treatment recurrent whose radiation. infused nanoliposome-encapsulated targets. being recurred tumor The therapeutic into chelated is of NanoLiposome, has very a initially licensed and radiation is directly is high via convection to and called, delivery and drug drug RNLTM, a with up for and deliver of chemotherapy cancer cancer patients surgical
as state trials, expertise nanoliposomes, products and internal our day and development clinical to by into in novel transaction. also that on CMC, in oncology of ways is leveraging model We transaction, with stated in met National those glioblastoma, case, in with mentioned this strategic expansion quarters. all leveraging our a carcinomatosis, this more Among and extensive sources and pipeline case NIH of development strategic the Cancer such frequently and commercial capabilities move technology drug the publicly drug in past excited efficient potentially this this It are the others, late rare formulation, and case consistent non-diluted this few introduction. in-licensing in aims, cost poorly a about finally, our virtual our Institute, in by applying aims track case, very doing development strong more have clinical a Texas of been then funding a via indications, and these via and exclusive and funding, stage focus record in one
at Second, substantially an that known medical have noted prefer have efficacy; we underserved check and new efficacy plan, this drug as information invest products and million three in least all market. a ingredients drug addressable technologies and transaction that $XXX that need; they key improve candidates in safety safety both previously third, boxes. address unmet First, our criteria: with candidates will Also, to three active extensive in meet combine These we these or pharmaceutical evolved they
clinical new and with details our status able we deal this regarding first transaction to quarter more the this of comports the And that precisely within in year. are transaction provide summary, I'll But deliver promptly were our previous momentarily. we pleased on technology guidance. the so particularly first our fiscal
our and current getting address in global now, I'd to So, XXXX to COVID-XX response the everyone's it. mind, to crisis this review, before now like Company's FYI specifically
to I on positive, impact results of December impact expect employees our tested am year XXXX. None of XX, and material XXXX, operations which coronavirus. a have we there's currently our material report fiscal no relieved our no ends the for been as that result on
of well substantially pandemic. implementation serving development Our a model us is the during virtual recent
our and our San for to occurred have remain support close Additionally, we arise potential supply with all Antonio of remain although staffed, at mitigations. our and lightly partners need employees schedules implement Be chain plans and open, No employees. coordination to Austin should sites, while facilities work continuity flexible company has have business them. we and our provide maximum risks in in the interruptions sure
provisions also law recently to passed CARES the are support provide of as Plus. it might the We to exploring how
for doctors, COVID-XX Health protective equipment protective distribution and by San other the trying protecting its such healthcare of also Scripps on to and the gloves frontline we others to affected as As practitioners business, our make final for we point regard are lion's to impact lines of that donated difference Diego are this a and Recently, pandemic. maintaining with workforce inventory coronavirus. to other to items our the a personal a with masks, share besides the nurses, surgical coping issue, our caring patients front
we work. know, ways health can other which to in after our has in La look part Health is system Jolla. a nonprofit We'll San in Plus Diego and presence Therapeutics and help you our integrated of continue San and many and Diego had Scripps private to As longtime do course communities the live a employees of we for look
Okay.
FY pivotal which productive Company. and review, So, this the marked the in let's XXXX to history the time of return
a In and innovative fact, cancers. of rare on battling for QX stage first delivery Plus company treatments revitalized patients and development clinical Therapeutics, pharmaceutical full new complex focused of discovery, was the quarter the the
Let La we summarize into some study of U.S. in assets, noncore substantial a for consolidated million development infrastructure. million injected $XX to consultants reliance we preserve of to me from cash and an in we Most from and drug operations Jolla, $XX Services. and Human Health to Also, Texas combination reimbursement liquidity. offering progress and the cost effective order XXXX. trusted a including balance the of meaning sheet ensure less in Department capital negotiating In million transactions selling made short, notably, the monetization on briefly closeout a deployments, $X.X engine increase virtualized of expensive a by we our scale and on development, completing California future and public down built model, efficient significantly slimmed fulltime
Our move a this. was Texas to key part of
We some to most and are researchers in the cancer proximity institutions. of geographic close renowned world's
$X.X research. Founded States in grants on X,XXX funding of whose research. research, As second the and to almost focused billion of state by cancer product has prevention, development ‘XX, Research in towards of since our new is government only home you Prevention commitment probably know, awarded federal Texas, academic to Institute United Texas oncology, Cancer public characterized a over cancer and funding has the CPRIT globally best statewide the
reiterate growth. I'll this, long-term strongly what has achieve all letter that financial summarize focus said to in shareholders. To Plus structure to now I and viability capability, I recent development cost just our Therapeutics believe the and
effect of important, approximately the these are in and serves two brain. nanoliposomes. directly provide energy drug brain. and novel both here without very That gamma morning. tumors, ahead to march these the BMEDA-chelated. radiation, being this life. through tissue are also one we When to precise XX-fold particularly deliver millimeter local to These delivered tumors side aimed is and rhenium-XXX. beta XX-hour further can two to to me the formulations isotopes specifically, chelator, drugs compounds a external unique standard [Technical characterized penetration let Difficulty] candidates or is transaction by beam this announced half [Technical both normal encapsulated kill XXx in Now, a a radioactive details which than get to chelates a can licensed third the chemistry, via And Difficulty], radiation family the incurred on BMEDA emitters. We've radiation is which radio These
show the the addition in live most multimodal to it [Technical the the a [Technical used various glioblastoma. standard this therapeutic randomized that Andrew [Technical beam of Difficulty] in, Dr. newly regime radiation studies external Texas lead nanoliposome Brenner X.X The recurrent five-month Difficulty] in the survival about compared Brenner, even with we radiation drug alone in basket initially is and today, [Technical consortium additional center improvement component his effective chemotherapy of Difficulty], Multiple brain bypassing Difficulty] normal by into Anderson infusing MD, [Technical directly brain external Furthermore, the Dr. with Center internationally times led assets glioblastoma. tumor, blood Difficulty] in targeted based the drug for was months rhenium PhD. are the modern of Cancer is Difficulty] developed modalities in [Technical treating fields. three licensed [Technical months Difficulty] at and and the Difficulty] MD for tumor barrier, multi-institutional By the [Technical renowned, and tissues the
delivered. effective if We know of dose an of glioblastoma clear the be drugs, cut. effectively In adequate the mechanism case can these is is action radiation against
very XX RNL received most In For patient the ongoing comparison, XXX clinical typically dose [Technical gray Difficulty] today contrast, [Technical to patient measured. important. gray. Difficulty] dosed glioblastoma, in recent -- the it’s radiation recurrent for that's trial protocols XXX is over the with
Antonio Anderson. Texas respect dose site at in to additional In are trial, two plans FDA a X finding in with at San with in Texas UT terms underway approved we of sites single U.S. in a clinical Southwestern School study MD and expand status this Medical currently to to Phase
in XX been delivered in beam fifth and the far The cohort. the we are by approximately at date external patients times typically dose radiation. thus In now the dose dosed cohort that now trial XX is dosing radiation is to the current have
serious Higher but standard these in terms have months of Thus patients And patients median efficacy two who of And that's been signals, respectively. doses are for trial. in in far, XX to RNL observed was in XX planned cohorts. tumor months received patients in complete nine first follow to no we compared events survived survival subsequent about the care. continue of adverse and with which achieved, the a coverage
technology review like may prevention and previously support. Difficulty] was Another third-party is thing there had well. of it we cancer research and [Technical further the be It Institute opportunities for funded by has as Texas, substantial really about this and
grant Phase X. glioblastoma. Currently award through continued from the X National for primarily clinical and offsets Cancer through million U.S. create the function the is but during recently development here Institutes of Health to for the NCI by of and Phase technology in will X the It’s awarded funded RNL recurrent National cost NIH in Phase The $X Institute Plus
plans about what ways the [Technical our with simultaneously, and maximum if namely X complete complete commercial the agency, finalize efficacy Phase availability. to product internally steps? data, the move supported studies trial required the work by next CMC late scalability explore to and with both accelerate definitive clinical the FDA development, safety clinical dose, for this and Difficulty] to and determine more tolerated and So, and the stage
appears and this Another product in & reason breast, ovarian several neck, for is liver our be candidate early. transaction still and so and leptomeningeal carcinomatosis, development technology enthusiastic this including although same preclinical this those, cancers, head is is quite indications, promising that additional in to team about
of candidate as in co-encapsulated nanoliposome and used and a a studied report neck as part the for support and and and cell plan well. another Therefore, that rhenium transaction head game-changer back these number it's preclinical is some treatment to carcinoma and Difficulty] has clinical tough this of in licensed additional as really the process. soon problems. we have refine be squamous of doxorubicin product could indications of chelated development other continue complete planning technology may that been for as development This [Technical a Furthermore, of the tumors
patents numerous worldwide Finally, peer reviewed these publications. assets in by are supported
move me our to let rest So, pipeline. on the of
number know, DocePLUS, a cancer. stabilized contains of may also PEGylated cell liposomal you pipeline small is our that X including a docetaxel is cancers lung ready As Phase target intended albumin which to
FDA Novartis’ cell of standard cell be our lung XXX(b)(X) orphan docetaxel, HYCAMTIN To has as platform, cancer, we we've $XXX this alternative in the pre-IND small to regulatory population a proprietary in treatment reformulation of indicating generated received care may According before, to TAXOTERE a for sales and pathway. Sanofi’s summarize million small have nanotechnology or relapsed and a patient for developed using topotecan feedback XXXX. and said an for what in Resources, product designation cancer FDA eligible new topotecan. being is Decision lung the that it's or option DocePLUS
management's proceed patients Prior lung therapy. with to had X to cell platinum been cancer small Phase who plan first announced line disease of after sensitive transaction, today's to trial have a progressed
management capital deployment. we environment, spend for the in way stockholder near-term believe for we adjust macroeconomic the needed plans rapidly return. maximize development our will prudence the current and do therefore QX However, pipeline, dictates uncertainty temporary in as while new and put such clinical capital with DocePLUS, to overall We'll We’ve assess that that a the situation. hold a the on markets assets in priorities in multiple proactively about
drug this CAELYX other potential the Regarding interested in first in DoxoPLUS, in version Europe. of as potential acquiring with our we're asset, generic discussions parties
of Additionally, and in-licensing other we review number to our a co-development opportunities continue geared pipeline. to expand
to turn Andrew, I'll you newly before word great me But, Chief Officer, over to about Andrew now, background team. give a arrived for just Sims, the financial let addition who’s our I it a And a Andrew's review. Financial do, brief
England Mazars, based a Public he understandable in including of offices. based on in Wales. firm. partner the Accountant border was advised global and and at and the both global variety Oxford, And advisory, Kingdom, in tax over educated in other he here health He and but raised was consulting England clients, a public He's transactions. financings he care an and acquisitions was an accounting lead and a and was York partner primarily and and previously Chartered companies, Andrew U.S., still originally New audited the audit Europe, in a Andrew United cross numerous has XX the Certified Accountant accent. audit,
welcome and So, it we turn to aboard you. over Andrew, you
